hot flashes market 2027
DelveInsight's 'Hot Flashes - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Hot Flashes in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Hot Flashes from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan
Study Period: 2016-2027
Hot Flashes - Disease Understanding and Treatment Algorithm
Hot flashes (HF) are often described as episodic sensations of heat, intense sweating, and flushing affecting the face and chest, which are often accompanied by palpitations and anxiety. Each particular episode lasts 3-10 minutes and episodes can recur with varying frequency. Some women experience hot flashes hourly or daily, whereas for others they may occur occasionally. The age at onset of hot flashes also varies from woman to woman. Hot flashes typically begin as the sudden sensation of heat centered on the upper chest and face. When moderate or severe, the hot flash rapidly become generalized, lasts from 2 to 4 minutes, and can be associated with profuse perspiration, palpitations, or anxiety.
The DelveInsight Hot Flashes market report gives the thorough understanding of the Hot Flashes by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Hot Flashes in the US, Europe, and Japan.
Hot Flashes Epidemiology
The Hot Flashes epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Prevalent Population of Hot Flashes Associated with Post-menopause and Severity-Specific Prevalent Population of Hot Flashes Associated with Post-menopause] scenario of Hot Flashes in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to DelveInsight, prevalent population of Hot Flashes associated with menopause in 7MM countries is expected to increase at a CAGR of 0.208% for the study period i.e. 2016-2027. As per the estimates, United States has the highest prevalent population of Hot Flashes associated with Post Menopause. Among the European countries, Germany had the highest prevalent population of Hot Flashes with 5,215,367 cases, followed by France which had prevalent population of 3,485,768 in 2016.
Hot Flashes Drug Chapters
This segment of the Hot Flashes report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The current therapeutic landscape of Hot Flashes associated with post-menopause can be divided into two major categories based on the class of drug; these are: Hormonal Therapies and Non-Hormonal Therapies. Detailed chapters of upcoming therapies such as TX-001HR (TherapeuticsMD), BHR-401 (Besins Healthcare), Donesta (Mithra Pharmaceuticals), Salubrin (PH-80; Pherin Pharmaceuticals), Fezolinetant (ESN364; Ogeda/Astellas) and NT-814 (Nerre Therapeutics) which are expected to launch during the forecast period [2018-2027] have also been covered in the report.
Hot Flashes Market Outlook
The Hot Flashes market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market size of Hot Flashes associated with Post-menopause in the seven major markets is expected to reach around USD 5,755.4 million by 2027. The United States accounts for the highest market size of Hot Flashes associated with Post-menopause in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan. The increased risk of Hormonal therapies (Breast Cancer, Dementia, and Cardiovascular Diseases) for the treatment of HF associated with postmenopause led to a decline in prescription Hormonal medication. This has led to a decline in the overall market size for the treatment of HF in the US from 2016 to 2022. However, DelveInsight's analysts estimate that the market is expected to show positive growth post 2022, due to the increased patient prevalence and to the expected launch of emerging Hormonal Therapies and targeted non-hormonal therapies.
Hot Flashes Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Expected launch of Hormonal therapies for Hot Flashes such as TherapeuticsMD (TX-001HR), Besins Healthcare (BHR-401), Mithra Pharmaceuticals (Donesta) and targeted Non-Hormonal Therapies such as Salubrin (PH-80; Pherin Pharmaceuticals), Fezolinetant (ESN364; Ogeda/Astellas) and NT-814 (Nerre Therapeutics) in the forecast period [2018-2027] will also create a positive impact on the Hot Flashes market.
Hot Flashes Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Hot Flashes Report Key Strengths
- 10 Years Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Key Cross Competition
- Market Size by Therapies
- Drugs Uptake
Hot Flashes Report Assessment
- Pipeline Product Profiles
- Key Products and Key Players
- Market Drivers and Barriers
Key Benefits
- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Hot Flashes market
- Organize sales and marketing efforts by identifying the best opportunities for Hot Flashes market
- To understand the future market competition in the Hot Flashes market.
